Financial Daily from THE HINDU group of publications
Friday, Feb 27, 2004

Cross Currency

Group Sites

Industry & Economy - Pharmaceuticals
Corporate - Outsourcing

Drugs: Outsourcing gains highlighted

Our Bureau

Hyderabad , Feb. 26

IN the backdrop of prohibitive costs of over $800 million per each new drug in the global market and the huge opportunity of over $53 billion in drugs going off-patent in the next five-six years, the US pharmaceutical and biotechnology industry finds big scope for outpartnering with the Indian industry and outsourcing the R&D and clinical trial services.

The General Counsel of the 1,500-company strong, US-based Biotechnology Industry Organisation (BIO), Mr Stephan E. Lawton, was of the view that the Indian biotechnology industry could outsource in the areas of chemistry, biogenerics and clinical trials.

Mr Stephan said the backlash in the US against outsourcing was only a short-term phenomenon, he said referring to what was happening in the IT sector.

Addressing newspersons at the global bio business forum - BioAsia - here on Thursday, he said the cost of clinical trials in the US was estimated at around $150 million per drug. It could be reduced by up to 60 per cent through cooperation with the Indian companies.

"Outsourcing in the area of drug discovery will not only reduce the cost of drugs being developed but also reduce the time to develop those drugs," he said.

However, he said the intellectual property (IP) protection and data efficacy protection were the key areas that need to be immediately addressed by India.

Stating that the existing patent regulations in India were not so strong to attract multinationals to outsource R&D activities, Mr Stephan expected the Indian authorities to act fast to address the issue.

The Managing Director of the US-based REDMONT Venture Partners, Mr Michael Alder, said, "Having law is not enough. It needs to be enforced in timely fashion to protect the IPR."

Stating that the drug discovery costs have to be brought down from the existing $800 million per drug to as low as $100 million, the President and Chief Executive Officer of the US-based Tranzyme Pharma, Mr Vipin K. Garg, said the Indian pharmaceutical and biotechnology industry has the opportunity of grabbing up to 20 per cent of this market space.

According to Mr Garg, the cost of clinical trials alone was accounting for nearly $150 million per drug in the US now.

Through outsourcing these services from the Indian industry, the cost could be reduced by 60 per cent.

Indian pharmaceutical industry, especially the Hyderabad industry, has the potential for grabbing the outsourcing opportunities in the areas of chemical synthesis, he said.

More Stories on : Pharmaceuticals | Outsourcing | Bio-tech & Genetics

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
TN annual rainfall average declining, says study

Bay of Bengal, Arabian Sea surface temperatures vary
Signs of summer
Nod for auto testing project
`Bengal industrial growth shows encouraging signs'
`Plastics are useful, if handled with care'
Pak team sees scope for boosting trade ties
Free trade with Thailand likely to begin from July
Sri Lanka Trade Centre opened in Chennai
Unctad keen to revive integrated plan for commodities to shore up African economy
Indo-Italian chamber in Kolkata to become operations office
Hyderabad to have Habitat Centre
Coastal Agenda Task Force awaits Karnataka Govt nod to submit report
RIL threatens to stop supplies to PSU oil marketing cos
Drugs: Outsourcing gains highlighted
National Forum to fight spurious drugs
NTPC gung-ho on coastal power plants — Simhadri experience a major confidence booster
Paucity of imported coal hits western region
Madurai-Tvm power project: Way cleared for implementation
Power exchange `possible' within five years
Cosmetic touch
Participatory approach vital to improve revenue collections in Karnataka: Panel
Applications invited from SSls for Visvesvaraya award
Move to identify isolated pockets of coal deposits
TRAI to set up special panel on CAS
IIM course helps IT cos combat attrition
AICTE may fix ceiling on technical education fees
Car buyer getting younger: JD Power
Private cos appointed consultants for defence housing projects
Aditya Birla hospital coming up near Pune
Spot gold may test support level
Media marketing body formed
Printing is now IT-enabled
IBP public offer subscribed 75 pc of issue size
Ambiguities in fertiliser policy — Major stumbling block to privatisation
IOC, GAIL cannot sell equity in ONGC for six months
`More corporate funding must to tackle issues in social sector'
`Affordable biotech needed to address socio-economic gaps'
In Hyderabad today
Sugar industry to utilise export quota to US
Campco ships arecanut consignment to Kabul
Spain eyes `big spending' tourists

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line